Pierre Azoulay


Pierre Azoulay


Pierre Azoulay is the International Programs Professor of Management at the MIT Sloan School of Management, and a Research Associate at the National Bureau of Economic Research.

His current research focuses on empirical studies of the supply of biomedical innovators, particularly at the interface of academia and the biopharmaceutical industry. He also is interested in the topic of academic entrepreneurship, having recently concluded a major study of the antecedents and consequences of academic patenting. In the past, he has investigated the impact of superstar researchers on the research productivity of their colleagues, and the outsourcing strategies of pharmaceutical firms, in particular the role played by contract research organizations in the clinical trials process.

At MIT Sloan, he teaches courses on competitive strategy and innovation strategy to the EMBA students and Sloan Fellows, as well as a PhD class on the economics of ideas, innovation, and entrepreneurship.

He holds a Diplôme d’Études Supérieures de Gestion from the Institut National des Télécommunications, an MA from Michigan State University, and a PhD in management from MIT.


"Beat COVID-19 Through Innovation."

Azoulay, Pierre and Benjamin Jones. Science, May 8, 2020.

"Self-Citation, Cumulative Advantage, and Gender Inequality in Science."

Azoulay, Pierre, and Freda B. Lynn. Sociological Science Vol. 7, (2020): 152-186. Download Paper.

"Scientific Grant Funding."

Azoulay, Pierre, and Danielle Li, MIT Sloan Working Paper 5927-19. Cambridge, MA: MIT Sloan School of Management, March 2020. Also NBER Working Paper #26889.

"The Rise of For-Profit Experimental Medicine."

Azoulay, Pierre and Ariel Y. Fishman, MIT Sloan Working Paper 6050-20. Cambridge, MA: MIT Sloan School of Management, March 2020. Also NBER Working Paper #26892.

Load More

Recent Insights

Ideas Made to Matter

MIT Sloan research about the coronavirus pandemic

The latest working papers from MIT Sloan faculty about the coronavirus/COVID-19 pandemic.

Read Article